Studies that may be of broad interest:
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis (2020)
"
Conclusion: The sequencing of ADT with prostate-directed RT has significant association with long-term PFS and MFS in localized PCa. Our findings favor use of an adjuvant over a neoadjuvant approach, without any increase in long-term toxicity."
(Authors include D.E. Spratt, a leading radiologist. 1,065 Patients reviewed.)
However, see also:
Neoadjuvant vs Concurrent ADT With Dose-Escalated Radiotherapy for Localized Prostate Cancer (2020)
'The investigators concluded, “In our study, there was no statistically significant difference in [biochemical relapse–free survival] between the two treatment groups. Similarly, no difference was seen in [overall survival] or late radiotherapy-related toxicities. On the basis of these results, both neoadjuvant and concurrent initiations of short-term ADT with dose-escalated [prostate] radiotherapy are reasonable standards of care for [localized prostate cancer].” '
_____________________________________________
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer (2020)
"
Conclusions: Consistent data are now present from diverse levels of evidence, which when viewed together, have demonstrated clinical utility of the GC in PCa. The utility of the GC is strongest for intermediate-risk PCa and postprostatectomy decision-making.
Patient summary: In this paper, we review the evidence of the Decipher genomic classification tool for men with prostate cancer. We found consistent evidence that the test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision-making."
(42 Studies with 30,407 Patients reviewed.)
_____________________________________________
Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer (2020)
"
Conclusions and relevance: In this cohort study of patients who underwent radical prostatectomy within 180 days of diagnosis for high-risk prostate cancer, radical prostatectomy for high-risk prostate cancer could be safely delayed up to 6 months after diagnosis."
(32,184 Patients in the study.)
Djin